CA2792539C - N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof - Google Patents

N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof Download PDF

Info

Publication number
CA2792539C
CA2792539C CA2792539A CA2792539A CA2792539C CA 2792539 C CA2792539 C CA 2792539C CA 2792539 A CA2792539 A CA 2792539A CA 2792539 A CA2792539 A CA 2792539A CA 2792539 C CA2792539 C CA 2792539C
Authority
CA
Canada
Prior art keywords
optionally substituted
alkyl
group
halogen
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2792539A
Other languages
English (en)
French (fr)
Other versions
CA2792539A1 (en
Inventor
Megumi Maruyama
Naoya Kinomura
Satoshi Nojima
Masahiro Takamura
Keisuke Kakiguchi
Hiroto Tatamidani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of CA2792539A1 publication Critical patent/CA2792539A1/en
Application granted granted Critical
Publication of CA2792539C publication Critical patent/CA2792539C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA2792539A 2010-03-11 2011-03-11 N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof Expired - Fee Related CA2792539C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2010-054177 2010-03-11
JP2010054177 2010-03-11
JP2010-285844 2010-12-22
JP2010285844 2010-12-22
PCT/JP2011/056497 WO2011111875A1 (en) 2010-03-11 2011-03-11 N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof

Publications (2)

Publication Number Publication Date
CA2792539A1 CA2792539A1 (en) 2011-09-15
CA2792539C true CA2792539C (en) 2017-04-18

Family

ID=44563664

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2792539A Expired - Fee Related CA2792539C (en) 2010-03-11 2011-03-11 N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof

Country Status (9)

Country Link
US (1) US8541585B2 (https=)
EP (1) EP2545046A4 (https=)
JP (1) JP5661791B2 (https=)
KR (1) KR101756495B1 (https=)
CN (1) CN102884059B (https=)
AU (1) AU2011225095C1 (https=)
CA (1) CA2792539C (https=)
TW (1) TWI475015B (https=)
WO (1) WO2011111875A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102180872B (zh) * 2011-04-01 2014-04-02 华中科技大学 [1,3,4]噁二唑类衍生物及其应用
CN104892589A (zh) 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
WO2016003296A1 (en) 2014-07-04 2016-01-07 Instytut Farmakologii Polskiej Akademii Nauk (quinoline or isoquinoline)sulfonamides of cyclic amines as antipsychotic drugs
CN105315267B (zh) * 2014-07-30 2019-06-04 江苏恩华药业股份有限公司 一种酰胺类衍生物及其应用
JP2019059672A (ja) * 2015-12-28 2019-04-18 大日本住友製薬株式会社 治療抵抗性うつ病等の治療薬
EP4263535A1 (en) 2020-12-17 2023-10-25 Astrazeneca AB N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides
JP7655885B2 (ja) * 2021-06-30 2025-04-02 住友ファーマ株式会社 脂肪族酸アミド誘導体を含有する医薬組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133061A (en) 1962-11-13 1964-05-12 Sterling Drug Inc Piperidine carboxamides and derivatives thereof
FR2285883A1 (fr) 1974-09-30 1976-04-23 Cerm Cent Europ Rech Mauvernay Nouveaux composes chimiques a activite bronchospasmolytique et antitussive, et procede pour leur obtention
WO1994007496A1 (en) 1992-10-07 1994-04-14 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
JP3162572B2 (ja) 1993-04-28 2001-05-08 住友製薬株式会社 インドロイルグアニジン誘導体
JPH08208602A (ja) 1994-10-18 1996-08-13 Sumitomo Pharmaceut Co Ltd インドロイルグアニジン誘導体
FR2729954B1 (fr) 1995-01-30 1997-08-01 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
US5861417A (en) * 1996-12-19 1999-01-19 Hoechst Marion Roussel, Inc. Heterocyclic substituted pyrrolidine amide derivatives
US6166037A (en) * 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
UA58476C2 (uk) 1997-10-09 2003-08-15 Санофі-Сентелябо Похідні 8-азабіцикло[3.2.1]октан-3-метанаміну, фармацевтична композиція та лікарський засіб
JPWO2002085890A1 (ja) 2001-04-20 2004-08-12 萬有製薬株式会社 ベンズイミダゾロン誘導体
FR2824828B1 (fr) * 2001-05-21 2005-05-20 Sanofi Synthelabo Nouveaux derives de piperidinecarboxamide, un procede pour leur preparation et les compositions pharmaceutiques les contenant
MXPA04005988A (es) 2001-12-19 2004-09-27 Lundbeck & Co As H 3,4-dihidro-1h-isoquinolin-2-il-derivados.
CA2551346A1 (en) 2003-12-31 2005-07-21 Warner-Lambert Company Llc N-substituted piperidine and piperazine derivatives
EP1797072A4 (en) 2004-09-17 2009-09-09 Exelixis Inc PYRAZOLKINASE MODULATORS AND USE METHOD
CA2628527A1 (en) 2005-11-17 2007-05-31 Arena Pharmaceuticals, Inc. Modulators of the h3 receptor useful for the treatment of disorders related thereto
JP5176281B2 (ja) 2006-03-23 2013-04-03 大日本印刷株式会社 リチウムイオン電池

Also Published As

Publication number Publication date
CA2792539A1 (en) 2011-09-15
CN102884059A (zh) 2013-01-16
US8541585B2 (en) 2013-09-24
AU2011225095C1 (en) 2017-01-19
EP2545046A4 (en) 2015-03-25
KR20130016234A (ko) 2013-02-14
US20120214790A1 (en) 2012-08-23
WO2011111875A1 (en) 2011-09-15
KR101756495B1 (ko) 2017-07-10
TW201139413A (en) 2011-11-16
JP5661791B2 (ja) 2015-01-28
AU2011225095B2 (en) 2016-05-19
AU2011225095A1 (en) 2012-09-27
EP2545046A1 (en) 2013-01-16
TWI475015B (zh) 2015-03-01
CN102884059B (zh) 2015-08-26
JP2013522165A (ja) 2013-06-13

Similar Documents

Publication Publication Date Title
CA2792539C (en) N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof
JP7646653B2 (ja) ピロリジン誘導体
CN116745280A (zh) 用于降解egfr的双功能化合物和相关使用方法
TW201311674A (zh) 吲唑－及吡咯并吡啶－衍生物及其醫藥用途
AU2021201424B2 (en) Aminopyridine derivatives and their use as selective alk-2 inhibitors
JP7840334B2 (ja) 芳香族複素環式化合物、薬学的組成物、及びその使用
CA3050021A1 (en) Compounds
WO2011050063A1 (en) 2-substituted-ethynylthiazole derivatives and uses of same
KR20240013134A (ko) 시그마 리간드로서 피리딘-술폰아미드 유도체
JP5715605B2 (ja) Ｎ−アシル環状アミン誘導体またはその医薬上許容される塩からなる医薬
EP4161937A1 (en) Pyrido[2,3-b] [1,4] oxazines or tetrahydropyrido[2,3-b][1,4] oxazepines as iap antagonists
CN119390705A (zh) 作为m4激动剂的5-氧杂-2-氮杂螺[3.4]辛烷衍生物
US20130150376A1 (en) Novel Sultam Compounds
AU2018393409A1 (en) Tetrahydropyrrole compound, preparation method therefor, pharmaceutical composition containing same, and use thereof
TWI912370B (zh) 芳香雜環類化合物、藥物組合物及其應用
WO2004000837A1 (ja) 新規なベンズオキサゾリノン誘導体
AU2006306497A1 (en) 3-piperidin-4-yl-indole ORL-1 receptor modulators
CN118076599A (zh) 二噁嗪类及其在治疗gba相关疾病中的用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160202

MKLA Lapsed

Effective date: 20190311